Key result
PAF antagonist BN 52021 reduces blood pooling ~53% in postischemic shock.
Why the study?
The role of platelet-activating factor (PAF) in postischemic blood pooling and associated cardio- and hemodynamic disturbances was unclear.
Does PAF receptor antagonist BN 52021 reduce blood pooling and hemodynamic disturbances in a dog model of postischemic shock?
Does PAF receptor antagonist BN 52021 reduce blood pooling and hemodynamic disturbances in a dog model of postischemic shock?
PAF receptor antagonism with BN 52021 reduces postischemic blood pooling and hemodynamic disturbances in a canine model of shock.
PAF induces venous pooling and hypotension akin to postischemic shock in dogs; hypothesis-generating for its role in human cardiogenic shock.
In experiments on dogs, i.v. administration of platelet-activating factor (PAF) (500 ng/kg) was shown to induce hypotension which, apart from decreased myocardial contractility, was characterized by blood pooling in veins (82.6 +/- 6.8 mL/kg). This was accompanied by restriction of venous return to the heart and reduction of cardiac output (CO). During postischemic shock the cardio- and hemodynamic disturbances were similar to those induced by i.v. administration of PAF. In the postischemic shock model, preliminary blockage of PAF receptors with the PAF receptor antagonist BN 52021 (6 mg/kg, i.v.) significantly decreased the amount of blood pooled in shock from 38.7 +/- 5 to 18.3 +/- 2 mL/kg (p less than 0.01). Simultaneously, the reduction of CO and blood pressure, induced by reperfusion of the continuously ischemized tissues of a rear limb, was less significant in pretreated vs. the nontreated group. The data suggest that PAF may be involved in postischemic blood pooling and that PAF antagonists could be used to correct postischemic cardio- and hemodynamic disturbances.
No takes yet. Share an insight, caveat, or question.
Sagach et al. (1991) studied Postischemic shock. PAF receptor antagonist BN 52021 vs. Nontreated group was evaluated on Amount of blood pooled in shock (mL/kg) (p=<0.01). In a dog model of postischemic shock, pretreatment with the PAF receptor antagonist BN 52021 significantly decreased blood pooling from 38.7 to 18.3 mL/kg (p<0.01).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: